CaumzCancer cachexia in patients with advanced incurable cancer
Development and Regulatory status
Phase III Clinical Trials
Cannabinoid receptor agonist presented in a CAUMZ™ Kit which comprises of capsules coated with 17mg delta-9-tetrahydrocannibinol and 5mg cannabidiol with a handheld Mighty Medic vaporiser
Cancer cachexia is present in approximately 50% of cancer patients during treatment, and nearly 100% of treated cancer patients at death. It accounts for at least 20% of deaths in neoplastic patients. Cancer cachexia impairs quality of life and response to therapy, increasing morbidity and mortality of cancer patients .
Cancer cachexia in patients with advanced incurable cancer